[go: up one dir, main page]

MX2009013186A - Derivados de piperazina y [1,4]diazepan como antagonistas de neurocinina. - Google Patents

Derivados de piperazina y [1,4]diazepan como antagonistas de neurocinina.

Info

Publication number
MX2009013186A
MX2009013186A MX2009013186A MX2009013186A MX2009013186A MX 2009013186 A MX2009013186 A MX 2009013186A MX 2009013186 A MX2009013186 A MX 2009013186A MX 2009013186 A MX2009013186 A MX 2009013186A MX 2009013186 A MX2009013186 A MX 2009013186A
Authority
MX
Mexico
Prior art keywords
sup
lower alkyl
hydrogen
halogen
substituted
Prior art date
Application number
MX2009013186A
Other languages
English (en)
Inventor
Hasane Ratni
Henner Knust
Matthias Nettekoven
Xihan Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009013186A publication Critical patent/MX2009013186A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula (I) (ver fórmula (I)) en donde R1 es hidrógeno o alquilo inferior; R2 es hidrógeno, fluoro, hidroxi o alquilo inferior; R3 es hidrógeno o alquilo inferior; R4 es -CHR5-A; R5 es hidrógeno, alquilo inferior, fluoro, CF3, CH2OH o cicloalquilo; A es arilo o heteroarilo, cuyos anillos son no sustituidos o sustituidos por (R6)O R6 puede ser igual o no cuando o sea más de uno, y es heteroarilo, alquilo inferior, alcoxi inferior, ciano, halógeno, alquilo inferior sustituido por halógeno, alcoxi inferior sustituido por halógeno o NR7R8 o es 1, 2 ó 3; R7, R8 son independientemente hidrógeno o alquilo inferior; R9 es alquilo inferior; R10 es alquilo inferior, alcoxi inferior o halógeno; n es 1 ó 2; m es 1 ó 2; o a una sal de adición con ácidos farmacéuticamente aceptables del mismo. La invención incluye todas las formas estereoisoméricas, incluyendo diastereoisómeros y enantiómeros individuales del compuesto de la fórmula (I) así como mezclas racémicas y no racémicas del mismo. Se ha encontrado que los presentes compuestos son antagonistas del receptor de NK-3 de alto potencial para el tratamiento de depresión, dolor, psicosis, mal de Parkinson, esquizofrenia, ansiedad y trastorno de hiperactividad por déficit de atención (ADHD).
MX2009013186A 2007-06-13 2008-06-04 Derivados de piperazina y [1,4]diazepan como antagonistas de neurocinina. MX2009013186A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07110143 2007-06-13
PCT/EP2008/056878 WO2008151969A1 (en) 2007-06-13 2008-06-04 Piperazine and [1,4] diazepan derivatives as nk antagonists

Publications (1)

Publication Number Publication Date
MX2009013186A true MX2009013186A (es) 2010-01-15

Family

ID=39540616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013186A MX2009013186A (es) 2007-06-13 2008-06-04 Derivados de piperazina y [1,4]diazepan como antagonistas de neurocinina.

Country Status (11)

Country Link
US (1) US7592345B2 (es)
EP (1) EP2167509A1 (es)
JP (1) JP2010529158A (es)
KR (1) KR101177977B1 (es)
CN (1) CN101679457B (es)
AU (1) AU2008263982B2 (es)
BR (1) BRPI0814253A2 (es)
CA (1) CA2690299A1 (es)
IL (1) IL202278A0 (es)
MX (1) MX2009013186A (es)
WO (1) WO2008151969A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015245901B2 (en) * 2014-04-10 2017-05-25 Dalhousie University Treatment of Parkinson's disease through ArfGAP1 inhibition using substituted piperazine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
GB0027701D0 (en) 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
GB0130261D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists

Also Published As

Publication number Publication date
JP2010529158A (ja) 2010-08-26
AU2008263982A1 (en) 2008-12-18
IL202278A0 (en) 2010-06-16
CN101679457B (zh) 2012-09-05
CA2690299A1 (en) 2008-12-18
AU2008263982B2 (en) 2012-09-27
EP2167509A1 (en) 2010-03-31
KR101177977B1 (ko) 2012-08-28
US7592345B2 (en) 2009-09-22
WO2008151969A1 (en) 2008-12-18
KR20100023957A (ko) 2010-03-04
US20080312216A1 (en) 2008-12-18
BRPI0814253A2 (pt) 2015-01-06
CN101679457A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
PH12012500690A1 (en) Positive allosteric modulators (pam)
MX366855B (es) Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
PH12015502001A1 (en) Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
HRP20140687T1 (hr) Derivati benzofurana
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
MX2010001080A (es) Pirrolidin-aril-eteres como antagonistas de receptor de nk3.
MY176030A (en) Substituted benzamide derivatives
AR070898A1 (es) Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
AR070635A1 (es) DERIVADOS DE PIRIDOPIRAZINONA QUE ESTIMULAN LA SECRECIoN DE INSULINA, MÉTODOS PARA OBTENERLOS, SU USO EN EL TRATAMIENTO DE LA DIABETES Y COMPOSICIONES FARMACEUTICAS.
MX354815B (es) Derivados heterociclicos como receptores asociados con las aminas traza (taars).
MX2015014353A (es) Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina.
PH12016501100B1 (en) Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators
MX2012001799A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3).
DE602006011725D1 (de) 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3-rezeptors
MX2011007272A (es) Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1.
MX2012006293A (es) Derivados de pirrolidina como antagonista del receptor nk-3.
MX2009013186A (es) Derivados de piperazina y [1,4]diazepan como antagonistas de neurocinina.
NZ592478A (en) Process for synthesis of amino-methyl tetraline derivatives
MX340508B (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2009006972A (es) Derivados de espiropiperidina como antagonistas de neuroquinina 3.
Kumar et al. Synthesis and evaluation of arylpiperazines derivatives of 3, 5-dioxo-(2H, 4H)-1, 2, 4-triazine as 5-HT1AR ligands
MX2011008178A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
ATE367163T1 (de) 4-(sulfanylpyrimidin-4-ylmethyl)morpholin- derivate und verwandte verbindungen als gaba- rezeptorliganden zur behandlung von angst, depression und epilepsie

Legal Events

Date Code Title Description
FG Grant or registration